Sensei Biotherapeutics, Inc. SNSE 深 滬
已收盤 01-30 16:00:00 美东时间
9.50
-0.160
-1.66%
華盛通- 最 高10.0292
- 今 開9.9037
- 成交量 6.95万股
- 最 低 9.03
- 昨 收 9.66
- 總市值 1198.23万
- 52周最高 18.35
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 5.00
- 委 比 1.27%
- 總股本 126.13万
- 歷史最高 530.00
- 量 比 0.84
- 振 幅 10.34%
- 歷史最低 5.00
- 每 手 1
- 風險率 1.48%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Akanda (NASDAQ:AKAN) stock rose 28.9% to $1.22 during Friday's pre-mar...
2025-12-05 20:05
Sensei Biotherapeutics GAAP EPS of -$3.62
Sensei Biotherapeutics press release (SNSE): Q3 GAAP EPS of -$3.62. Cash, cash equivalents and marketable securities were $25.0 million as of September 30, 2025, as compared to $41.3 million as of Dec...
2025-11-14 20:46
Sensei Biotherapeutics Reports Third Quarter 2025 Financial Results
Sensei Biotherapeutics reported Q3 2025 financial results, announcing the discontinuation of solnerstotug development and initiating a strategic review to maximize shareholder value. The company reduced its workforce by 65% to preserve cash. Financial highlights include $25.0 million in cash, reduced R&D expenses to $2.5 million, G&A expenses at $2.3 million, and a net loss of $4.6 million. Key financial metrics reflect cost reductions and ongoin...
2025-11-14 12:30
HC Wainwright & Co. Downgrades Sensei Biotherapeutics to Neutral
HC Wainwright & Co. analyst Matthew Keller downgrades Sensei Biotherapeutics (NASDAQ:SNSE) from Buy to Neutral.
2025-10-31 00:27
Sensei Biotherapeutics Board Determines To Discontinue Development Of Solnerstotug And Initiate Comprehensive Review Of Strategic Alternatives To Maximize Shareholder Value
Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical-stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that its Board of Directors
2025-10-30 21:10
Sensei Biotherapeutics Releases Results From The Phase 1/2 Dose Expansion Study Of Solnerstotug Presented At ESMO 2025. The Data Addressed The Critical Challenge Of Secondary Resistance To Immune Checkpoint Inhibitors, Where Treatment Success Rates Are Typically Below 5%
Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical-stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced results from the dose
2025-10-17 20:16
Sensei Biotherapeutics Reports New Clinical Results Highlighting Durable Progression Free Survival Data for Solnerstotug in PD-(L)1 Resistant Tumors at the ESMO Congress 2025
Sensei Biotherapeutics announced promising results from the dose expansion portion of its Phase 1/2 trial for solnerstotug, a VISTA-targeting monoclonal antibody. The 15 mg/kg dose showed a 6-month progression-free survival (PFS) of 50% in PD-(L)1 refractory patients, with all clinical responses, including a complete response, occurring in this cohort. The safety profile was favorable, with only mild cytokine release syndrome (CRS) events reporte...
2025-10-17 12:00
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Adaptimmune Therapeutics (NASDAQ:ADAP) stock moved upwards by 32.1% to...
2025-10-09 05:06
Sensei Biotherapeutics to Host Virtual KOL Event to Discuss Full Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors on October 20, 2025
Sensei Biotherapeutics will host a virtual KOL event on October 20, 2025, featuring discussions on immunotherapy-resistant solid tumors, updates on Phase 2 studies, and data from Phase 1/2 trials of solnerstotug, a VISTA-targeting antibody. The event will include a Q&A session. Sensei's TMAb platform develops therapeutics to target the tumor microenvironment, with solnerstotug selectively blocking VISTA in low pH conditions to activate T cells ag...
2025-09-23 11:30
Sensei Biotherapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
<p>Sensei Biotherapeutics announced that John Celebi, its CEO, will participate in 1x1 investor meetings at the H.C. Wainwright Global Investment Conference on September 8, 2025. An on-demand corporate presentation will be available on the company's website starting September 5, 2025, and a webcast replay will be accessible for 90 days. The company focuses on developing next-generation cancer therapeutics using its TMAb platform, with its lead ca...
2025-09-03 12:00
